The MedTech industry continues to see significant mergers, acquisitions, and divestments, driven by the need for innovation, portfolio realignment, and strategic growth.
In this post, we highlight some of the most impactful moves that are shaping the MedTech landscape.
1. Baxter’s Strategic Moves: Growth Forecast and Major Divestments
Baxter is making headlines with its optimistic growth forecast, driven by robust demand for its medical devices. Alongside this, the company is streamlining its operations by selling its Vantive Kidney Care unit to Carlyle for $3.8 billion. These moves position Baxter to focus on its core strengths while capitalizing on key market opportunities.
Read more about Baxter’s divestments and growth forecast
Read more about Baxter's Vantive sale
2. Johnson & Johnson Expands Its Cardiac Portfolio
Johnson & Johnson continues its strategic push into the cardiac market by acquiring V-Wave, a company specializing in heart failure treatment technologies. This acquisition, valued up to $1.1 billion, reinforces J&J’s commitment to enhancing its cardiovascular product offerings. This move comes on the heels of J&J’s previous acquisitions, further solidifying its position in the heart failure treatment market.
Read more about J&J’s acquisition of V-Wave
3. Zimmer Biomet and Stryker Strengthen Their Portfolios
Both Zimmer Biomet and Stryker have been busy enhancing their orthopedic and pain management portfolios through strategic acquisitions.
Zimmer Biomet has signed a definitive agreement to acquire OrthoGrid Systems, which will bolster its orthopedic solutions.
Meanwhile, Stryker has been making waves with two major deals: the acquisition of Vertos Medical, expanding its back pain treatment capabilities, and adding new products to its foot and ankle portfolio.
Read more about Zimmer Biomet and Stryker’s acquisitions - Orthogrid
Read more about SYK's acquisition of Vertos
Read more about SYK's F&A move
These moves reflect a broader industry trend of consolidation in the orthopedic and pain management sectors.
4. Edwards Lifesciences Realigns Its Business
Edwards Lifesciences is pursuing an aggressive expansion of its TAVR (Transcatheter Aortic Valve Replacement) technology by acquiring Genesis. At the same time, the company is divesting its critical care business to BD, which includes the layoffs of 500 employees as part of a realignment strategy. This balancing act between acquisitions and divestments allows Edwards to focus on its core growth areas while shedding less profitable segments.
Read more about Edwards Lifesciences’ acquisitions and divestments
Read more about Edwards Lifesciences’ acquisitions and divestments
5. Nevro and Solventem Adjust to Market Shifts
Nevro is considering the sale of its spinal cord stimulation business as the pain management market undergoes changes. This potential sale could be a significant reshuffle in the spinal cord therapy space.
Solventem, meanwhile, recently reported its first standalone Q2 earnings, navigating both growth opportunities and challenges after its split.
Read more about Solventem’s earnings report
Read more about Nevro’s potential sale
6. Boston Scientific Nears Completion of Silk Road Medical Acquisition
Boston Scientific is set to close its $1.26 billion acquisition of Silk Road Medical, a deal that strengthens its position in the neurovascular space. This acquisition will allow Boston Scientific to expand its presence in stroke prevention and treatment technologies, a rapidly growing market.
Read more about Boston Scientific’s acquisition of Silk Road Medical
Conclusion
The MedTech industry’s M&A activity remains robust, with major players making moves to strengthen their portfolios, enter new markets, and divest non-core assets.
These strategic moves underscore the evolving landscape of the MedTech sector, where innovation and consolidation are key to staying competitive.
Stay tuned as we continue to monitor the latest M&A developments reshaping the MedTech world.